In-depth characterisation of biliary strictures and hepato‑pancreato‑biliary focal lesions to support new diagnostic technologies
Official title: In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers
Run by University of Nottingham · NCT07206355 · Data updated 2026-11-12
This project will collect detailed imaging and tissue data from adults with suspected bile duct, liver, pancreatic, or gallbladder lesions to help develop and test better diagnostic tools.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | University of Nottingham Academic / other |
| Locations | 1 site (Nottingham) |
| Status | Recruiting |
| Started | January 25, 2026 |
| Main results expected | September 30, 2028 |
| Study ends | September 30, 2030 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT07206355 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 16 and over who are attending Nottingham University Hospitals for diagnosis or surgical treatment of suspected biliary strictures or other HPB focal lesions are ideal candidates.
✕Probably not a fit
People without suspected HPB lesions, those not having tissue sampling or diagnostic imaging as part of care, or patients treated outside Nottingham are unlikely to receive direct benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will enroll adults (≥16) attending Nottingham University Hospitals with suspected biliary strictures or other hepato‑pancreato‑biliary (HPB) focal lesions, including those undergoing surgical resection. It will collect clinical information, imaging, endoscopic and surgical tissue samples, and linked pathology and molecular profiling obtained as part of routine care. The aim is to characterise features that distinguish benign from malignant lesions and to provide well‑annotated material for development of imaging, sampling, and molecular diagnostic technologies. No experimental treatments are given; participation involves consenting to use of data and samples collected during standard diagnosis and treatment.
Why it matters
Potential benefit: If successful, this work could enable earlier and more accurate diagnosis of HPB cancers and improve matching of patients to targeted therapies.
How similar studies have gone: Prior research has identified actionable molecular targets in cholangiocarcinoma and pancreatic cancer, but comprehensive paired imaging, tissue, and molecular datasets specifically collected to drive new diagnostic devices are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 16 years and over * Ability to provide informed consent to participate in the study * Patients attending Nottingham University Hospitals NHS Trust (NUH) as part of standard clinical care for either: * the diagnosis and treatment of suspected biliary stricture or any focal lesion in the Hepato-Pancreato-Biliary (HPB) tract (clinically / radiologically) including liver or pancreatic lesion or pancreatic cyst * surgical resection treatment of liver, pancreas, or gall bladder including Whipple Procedure (pancreaticoduodenectomy surgery), gall bladder resection (cholecystectomy), hepatic resection Exclusion Criteria: No exclusion criteria
Where it's running
-
University of Nottingham
Nottingham, United Kingdom Recruiting
Study contacts
- Principal investigator: Guruprasad P Aithal, MBBS, MD, PhD — University of Nottingham
- Study coordinator: Saikat Mandal, MBBS, MD, MRCEM
- Email: saikat.mandal@nottingham.ac.uk
- Phone: (+44) 0115 970 9900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YMN-136 vaccine for advanced liver, biliary tract, and pancreatic cancers
A first-in-human dose-escalation study tests whether the YMN-136 vaccine is safe and tolerable for adults with unresectable advanced liver, biliary tract, or pancreatic cancers who have progressed on standard therapies or cannot receive them.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
PET imaging that targets CLDN18.2 to find stomach, pancreatic, bile-duct, and esophageal cancers
This project will try a CLDN18.2-targeted PET scan in adults with suspected or confirmed gastric, pancreatic, bile-duct, or esophageal cancer (and some healthy volunteers) to see if it can show CLDN18.2-positive tumors.
-
Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas
This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.
-
Using bile analysis to diagnose unclear narrowings of the bile ducts
This project will test whether analyzing bile with molecular 'omics' together with routine biliary brushings or biopsies can help find cancer in people with indeterminate biliary strictures.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.